Maravai Lifesciences Holdings (MRVI) Short term Debt (2021 - 2026)

Maravai Lifesciences Holdings' Short term Debt history runs 6 years deep, the most recent figure standing at $5.4 million for Q1 2026.

• On a quarterly basis, Short term Debt changed 0.0% year-over-year to $5.4 million in Q1 2026; TTM through Mar 2026 was $5.4 million, a 0.0% change from a year earlier, with the FY2025 full-year figure at $5.4 million, changed 0.0% from the prior year.
• Short term Debt steadied at $5.4 million in Q1 2026 per MRVI's latest filing, from $5.4 million in the prior quarter.
• Across five years, Short term Debt topped out at $34.7 million in Q1 2022 and bottomed at $5.4 million in Q3 2022.
• The 5-year median for Short term Debt is $5.4 million (2022), against an average of $8.9 million.
• Biggest YoY gain for Short term Debt was 2576.96% in 2022; the steepest drop was 84.38% in 2022.
• Year by year, Short term Debt stood at $5.4 million in 2022, then changed by 0.0% to $5.4 million in 2023, then changed by 0.0% to $5.4 million in 2024, then changed by 0.0% to $5.4 million in 2025, then changed by 0.0% to $5.4 million in 2026.
• Per Business Quant, the three latest MRVI Short term Debt figures stand at $5.4 million (Q1 2026), $5.4 million (Q4 2025), and $5.4 million (Q3 2025).